AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29337426 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 80
Study 27576774 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine therapy (75 to 325 mg aspirin daily)
Number of subjects: 11648
Study 27576774 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine therapy
Number of subjects: 11648
Study 27576774 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 11648
Study 27576774 — intervention group
Group type: COMPARATOR
Intervention: Stent thrombosis
Number of subjects: 11648
Study 27576774 — intervention group
Group type: COMPARATOR
Intervention: Death
Number of subjects: 11648
Study 24887576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose contrast medium (400 mgI/kg) with 80 kV(p)
Number of subjects: 63
Study 22729169 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pupil contact lens
Number of subjects: 22
Study 22729169 — intervention group
Group type: COMPARATOR
Intervention: Monovision
Number of subjects: 22
Study 19707728 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h Evidence Based Medicine (EBM) Workshop
Number of subjects: 0
Study 18174489 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilization (VEM)
Number of subjects: 71
Study 18174489 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study 16168039 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy and antidepressants
Number of subjects: 257
Study 16168039 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 257
Study 13129987 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bipolar magnets
Number of subjects: 101
Study 13129987 — intervention group
Group type: COMPARATOR
Intervention: Sham magnets
Number of subjects: 101
Study 10456592 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (ear acupuncture)
Number of subjects: 72
Study 10456592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 72
Study 8754963 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 60
Study 8754963 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 60
Study 8754963 — intervention group
Group type: COMPARATOR
Intervention: oxymetazoline
Number of subjects: 60
Study 1817903 — intervention group
Group type: EXPERIMENTAL
Intervention: Articain
Number of subjects: 1500
Study 1817903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocain
Number of subjects: 1500
Study 1817903 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown anesthetic solutions
Number of subjects: 1500
Study 6983500 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (300 mg at night)
Number of subjects: 89
Study 6983500 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (two tablets 12-hourly for seven days)
Number of subjects: 89
Study 31442001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative antibiotics prescribed by 95.0% of surgeons
Number of subjects: 208
Study 31442001 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics prescribed by 73.6% of respondents
Number of subjects: 208
Study 31442001 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing intraoperative antibiotic use
Number of subjects: 208
Study 31442001 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing postoperative antibiotic use
Number of subjects: 208
Study 29085957 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate teriparatide therapy
Number of subjects: 13
Study 29085957 — intervention group
Group type: COMPARATOR
Intervention: Delayed teriparatide therapy
Number of subjects: 13
Study 29085957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 27060082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis synovial fluid (SF)
Number of subjects: 12
Study 27060082 — intervention group
Group type: COMPARATOR
Intervention: Osteoarthritis synovial fluid (SF)
Number of subjects: 12
Study 27060082 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of citrullinated proteins
Number of subjects: 12
Study 27060082 — intervention group
Group type: COMPARATOR
Intervention: Citrullinated histone H3.3 (H3F3A)
Number of subjects: 12
Study 25567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m² q3w (standard group)
Number of subjects: 88
Study 25567311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m² q3w (study group)
Number of subjects: 88
Study 25567311 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m² q3w or 100 mg/m² q3w
Number of subjects: 88
Study 22765322 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management augmented with emotionally focused therapy (MM + EFT)
Number of subjects: 24
Study 22765322 — intervention group
Group type: COMPARATOR
Intervention: Medication management alone (MM)
Number of subjects: 24
Study 20178543 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy using the Hohl instrument
Number of subjects: 257
Study 18382805 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (1-3 doses with a one-month interval)
Number of subjects: 200
Study 18382805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 200
Study 18382805 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (for patients who failed to respond to placebo)
Number of subjects: 200
Study 16152755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 498
Study 16152755 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 498
Study 16152755 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (stopped)
Number of subjects: 498
Study 11850288 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg telithromycin, once daily for 5 days (Group A)
Number of subjects: 24
Study 11850288 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg telithromycin, once daily for 5 days (Group B)
Number of subjects: 24
Study 11850288 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg telithromycin, once daily for 5 days (Group C)
Number of subjects: 24
Study 11850288 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg telithromycin, once daily for 5 days (Group D)
Number of subjects: 24
Study 12047398 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg) administered during insulin clamp studies
Number of subjects: 14
Study 12047398 — intervention group
Group type: COMPARATOR
Intervention: Control (without misoprostol) during insulin clamp studies
Number of subjects: 14
Study 9583286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels (374 +/- 11.9 mg/dL)
Number of subjects: 131
Study 9583286 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ischaemic heart disease)
Number of subjects: 131
Study 9583286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels > 300 mg percent
Number of subjects: 131
Study 9583286 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-vessel disease
Number of subjects: 131
Study 7866602 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 0
Study 7866602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Number of subjects: 0
Study 7866602 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 0
Study 7866602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2768616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate (Ritalin)
Number of subjects: 25
Study 2768616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg methylphenidate (Ritalin)
Number of subjects: 25
Study 2768616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 687500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 60 or 90 mg
Number of subjects: 2
Study 687500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 210 or 240 mg
Number of subjects: 2
Study 687500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 60 mg
Number of subjects: 2
Study 687500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 210 mg
Number of subjects: 2
Study 30962030 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dimensional technique
Number of subjects: 57
Study 30962030 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional technique
Number of subjects: 57
Study 30962030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 57
Study 28198583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tube based on the Khine formula (Group R)
Number of subjects: 100
Study 28198583 — intervention group
Group type: COMPARATOR
Intervention: Cuffed endotracheal tube that was a half-size (0.5 mm ID) smaller (Group S)
Number of subjects: 100
Study 25769746 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-sodium lunches (29% to 61% sodium reduction)
Number of subjects: 74
Study 25769746 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-sodium lunches
Number of subjects: 74
Study 25769746 — intervention group
Group type: COMPARATOR
Intervention: Regular foods (control group)
Number of subjects: 74
Study 23377843 — intervention group
Group type: EXPERIMENTAL
Intervention: Common identity treatment (to enhance their sense of commonality)
Number of subjects: 86
Study 23377843 — intervention group
Group type: COMPARATOR
Intervention: Control (standard health information)
Number of subjects: 86
Study 21319929 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attributional style condition
Number of subjects: 0
Study 21319929 — intervention group
Group type: COMPARATOR
Intervention: Negative attributional style condition
Number of subjects: 0
Study 19243891 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.6 g/kg)
Number of subjects: 48
Study 19243891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19243891 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 48
Study 19243891 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol effects on prolactin, cortisol, and adrenocorticotropin stress response
Number of subjects: 48
Study 14739421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 14739421 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 0
Study 11349340 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly communication for 6 months via a totally automated, computer‐based voice system.
Number of subjects: 298
Study 11349340 — intervention group
Group type: COMPARATOR
Intervention: Physical activity promotion counseling (control group).
Number of subjects: 298
Study 9009543 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT/Rx Firm Molded Insoles with magnetic foil
Number of subjects: 34
Study 9009543 — intervention group
Group type: COMPARATOR
Intervention: PPT/Rx Firm Molded Insoles without magnetic foil (Control)
Number of subjects: 34
Study 8270918 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (antibiotic treatment for asymptomatic UTI)
Number of subjects: 20
Study 8270918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 20
Study 2887520 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol (1 to 4 mg/day)
Number of subjects: 31
Study 2887520 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 to 200 mg/day)
Number of subjects: 31
Study 2887520 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol
Number of subjects: 31
Study 2887520 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 31
Study 31298727 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas Bubble Escape (GBE) sign group
Number of subjects: 50
Study 31298727 — intervention group
Group type: COMPARATOR
Intervention: No Gas Bubble Escape (no GBE) sign group
Number of subjects: 50
Study 31298727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at 1 month
Number of subjects: 50
Study 29624493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% BID (twice a day)
Number of subjects: 300
Study 29624493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% TID (three times a day)
Number of subjects: 300
Study 29624493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% QID (four times a day)
Number of subjects: 300
Study 29624493 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% TID (three times a day)
Number of subjects: 300
Study 29624493 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.5% TID (three times a day)
Number of subjects: 300
Study 26847148 — intervention group
Group type: EXPERIMENTAL
Intervention: LC (Traditional Chinese Medicine)
Number of subjects: 57
Study 26847148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard treatment without LC)
Number of subjects: 57
Study 25385295 — intervention group
Group type: EXPERIMENTAL
Intervention: hUC‐MSC therapy with anti‐inflammatory treatment
Number of subjects: 23
Study 25385295 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti‐inflammatory treatment only)
Number of subjects: 23
Study 23209076 — intervention group
Group type: EXPERIMENTAL
Intervention: C312M vaccination via oral, immersion, and oral plus immersion routes
Number of subjects: 0
Study 23209076 — intervention group
Group type: EXPERIMENTAL
Intervention: C312M vaccination
Number of subjects: 0
Study 20837585 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmeted
Number of subjects: 70
Study 20837585 — intervention group
Group type: COMPARATOR
Intervention: Actively repositioned
Number of subjects: 70
Study 17509404 — intervention group
Group type: EXPERIMENTAL
Intervention: RealSeal
Number of subjects: 26
Study 17509404 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta-percha
Number of subjects: 26
Study 16206349 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weekly HMW hyaluronan injections (O4, n = 128)
Number of subjects: 372
Study 16206349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weekly HMW hyaluronan injections followed by one arthrocentesis (O3A1, n = 120)
Number of subjects: 372
Study 16206349 — intervention group
Group type: COMPARATOR
Intervention: 4 arthrocenteses without injection (control group, A4, n = 124)
Number of subjects: 372
Study 16206349 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weekly HMW hyaluronan injections (O4)
Number of subjects: 372
Study 16206349 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 372
Study 12675978 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 85
Study 12675978 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 85
Study 10789884 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 0
Study 10789884 — intervention group
Group type: COMPARATOR
Intervention: Control tasks (somatically matched)
Number of subjects: 0
Study 8814843 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-laser vaporization of the prostate
Number of subjects: 102
Study 8814843 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 102
Study 1381763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg b.i.d.
Number of subjects: 14
Study 1381763 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg b.i.d.
Number of subjects: 14
Study 1381763 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 14
Study 6371289 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 18
Study 6371289 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.5 mg
Number of subjects: 18
Study 6371289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3531851 — intervention group
Group type: EXPERIMENTAL
Intervention: PK10169 low-molecular-weight heparin
Number of subjects: 100
Study 3531851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29803635 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 15
Study 29803635 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study 27829318 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 50
Study 27829318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25707875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (rATG, Thymoglobulin)
Number of subjects: 227
Study 25707875 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 227
Study 25707875 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall graft survival
Number of subjects: 227
Study 25707875 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall graft survival at 5 years with either induction therapy
Number of subjects: 227
Study 23128528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylated p14ARF gene promoter
Number of subjects: 111
Study 23128528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylated O6‐MGMT gene promoter
Number of subjects: 111
Study 23128528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation of one or more of the genes from the set p14ARF, RASSF1A and APC1A
Number of subjects: 111
Study 20337877 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the BOOST II trial
Number of subjects: 100
Study 20337877 — intervention group
Group type: COMPARATOR
Intervention: Not participating in the BOOST II trial
Number of subjects: 100
Study 17595381 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT) for 2 weeks
Number of subjects: 0
Study 17595381 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (age-matched)
Number of subjects: 0
Study 17595381 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 0
Study 16815320 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg sumatriptan
Number of subjects: 12
Study 16815320 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sumatriptan
Number of subjects: 12
Study 16815320 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 12
Study 16815320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12665269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fluvent) at a daily dose of 22 microg
Number of subjects: 10
Study 12665269 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (Becotide) at a daily dose of 400 microg
Number of subjects: 10
Study 9716142 — intervention group
Group type: EXPERIMENTAL
Intervention: Captured ELISA using kistrin to measure platelet microparticles (PMP)
Number of subjects: 12
Study 9716142 — intervention group
Group type: COMPARATOR
Intervention: Flow cytometry
Number of subjects: 12
Study 9716142 — intervention group
Group type: COMPARATOR
Intervention: Normal washed platelets (10^8)
Number of subjects: 12
Study 9716142 — intervention group
Group type: COMPARATOR
Intervention: Outdated platelets
Number of subjects: 12
Study 9716142 — intervention group
Group type: COMPARATOR
Intervention: Fresh blood from healthy donors
Number of subjects: 12
Study 9716142 — intervention group
Group type: COMPARATOR
Intervention: Heparin and protamine
Number of subjects: 12
Study 9716142 — intervention group
Group type: COMPARATOR
Intervention: Pericardial blood
Number of subjects: 12
Study 8110581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 0
Study 8110581 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0
Study 8110581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2577570 — intervention group
Group type: EXPERIMENTAL
Intervention: Double stapling technique
Number of subjects: 110
Study 2577570 — intervention group
Group type: COMPARATOR
Intervention: EEA stapler
Number of subjects: 110
Study 2577570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann procedure using stapler techniques
Number of subjects: 110
Study 7100 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol t.i.d.
Number of subjects: 18
Study 7100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31724168 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational package
Number of subjects: 70
Study 31724168 — intervention group
Group type: COMPARATOR
Intervention: Training on breastfeeding and normal delivery (Control)
Number of subjects: 70
Study 30353843 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulated learning campaign on healthy eating
Number of subjects: 30
Study 30353843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 29901379 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg, 1 tablet a day for 4 weeks, then increased to 2 tablets a day for the next 4 weeks)
Number of subjects: 41
Study 29901379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosing schedule as donepezil)
Number of subjects: 41
Study 24903024 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of physical training
Number of subjects: 21
Study 22209127 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 0
Study 22209127 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive writing
Number of subjects: 0
Study 22209127 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional writing group (combined expressive and positive writing)
Number of subjects: 0
Study 22209127 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 0
Study 20456105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pads with different amounts of lotion applied; evaluated for 3 hours using the BTK protocol.
Number of subjects: 0
Study 20456105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pads with AGM core; evaluated for lotion transfer.
Number of subjects: 0